ADMA Biologics Faces Allegations of Financial Misconduct
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Globenewswire
- Allegations of Financial Misconduct: ADMA Biologics is accused of channel stuffing to misrepresent a 3% revenue decline as a 20% growth, leading to significant investor losses and highlighting severe transparency issues within the company.
- Independent Research Unveils Truth: A report by Culper Research indicates that ADMA's ASCENIV revenues actually declined by 3% in 2025, contradicting the reported 20% growth, revealing a critical disconnect between the company and its distributors.
- Legal Action Initiated: A securities class action has been launched on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, with a deadline for claims set for August 10, 2026, likely impacting the company's stock price negatively.
- Market Confidence Eroded: The significant discrepancy between ADMA's financial reports and independent research findings has severely undermined investor trust, potentially leading to substantial stock price volatility and affecting future fundraising capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Revenue Growth Under Scrutiny Amid Short-Seller Claims
- Revenue Growth Projection: ADMA Biologics projects a 20% revenue growth for ASCENIV in 2025, reaching $362.5 million; however, independent research suggests a potential 3% decline, raising serious concerns about the company's financial transparency among investors.
- Lawsuit Allegations: A securities class action has been filed against ADMA, alleging misleading statements regarding ASCENIV's revenue recognition and internal control effectiveness during the period from August 9, 2024, to March 25, 2026, which has left investors facing significant losses.
- Channel Stuffing Claims: A report by Culper Research indicates that ADMA may have engaged in channel stuffing by shipping excess ASCENIV to distributors, creating a false appearance of demand, which is believed to be a primary reason for the inflated revenue figures, further intensifying market skepticism about its financial reporting.
- Related Party Transaction Concealment: The lawsuit also alleges that ADMA failed to disclose related party transactions with Genesis BioPharma Services in SEC filings, despite direct ties to the company's Vice Chairman, which could undermine investor trust in the company's governance practices.
See More
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Kahn Swick & Foti LLC has initiated a class action lawsuit against ADMA Biologics on behalf of investors who suffered losses due to undisclosed material information between August 9, 2024, and March 25, 2026.
- Allegations Details: The lawsuit alleges that ADMA engaged in undisclosed related party transactions, utilized channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about its business and prospects.
- Legal Proceedings: The case is pending in the United States District Court for the District of New Jersey, and investors have until August 10, 2026, to apply for lead plaintiff status to participate in any potential recovery.
- Law Firm Background: Kahn Swick & Foti is recognized as one of the premier securities litigation law firms in the U.S., ranked among the top ten nationally based on total settlement value, focusing on recovering losses for investors affected by corporate fraud or misconduct.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses and damaging the company's reputation.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder of ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Class Action Filed Against ADMA Biologics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit alleges that ADMA engaged in undisclosed related party transactions, used channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, which severely undermines operational transparency and investor confidence.
- Stock Price Impact: Following the publication of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, indicating market concerns regarding the company's financial health.
- Next Steps: Affected investors are encouraged to contact Bragar Eagel & Squire for more information, demonstrating the firm's commitment to protecting investor rights and providing legal support.
See More
ADMA Biologics Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a class action lawsuit against ADMA Biologics on July 7, 2026, for investors who purchased securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false statements regarding its business operations and financial stability, resulting in artificially inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to the defendants' misrepresentations, ADMA's securities traded at inflated prices, leading to significant losses for investors when the truth was revealed, highlighting serious issues regarding the company's transparency and compliance.
- Participation Requirements: Investors are encouraged to act promptly and submit forms to join the lawsuit, and those wishing to serve as lead plaintiffs must file by August 10, 2026, indicating the company's commitment to shareholder rights and proactive engagement in legal processes.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has extensive experience in handling class actions, demonstrating its strong capabilities in the legal field and commitment to protecting investor rights.
See More
ADMA Biologics Revenue Growth Under Scrutiny Amid Short-Seller Claims
- Revenue Growth Projection: ADMA Biologics projects a 20% revenue growth for ASCENIV in 2025, reaching $362.5 million; however, independent research suggests a potential 3% decline, raising serious concerns about the company's financial transparency among investors.
- Lawsuit Allegations: A securities class action has been filed against ADMA, alleging misleading statements regarding ASCENIV's revenue recognition and internal control effectiveness during the period from August 9, 2024, to March 25, 2026, which has left investors facing significant losses.
- Channel Stuffing Claims: A report by Culper Research indicates that ADMA may have engaged in channel stuffing by shipping excess ASCENIV to distributors, creating a false appearance of demand, which is believed to be a primary reason for the inflated revenue figures, further intensifying market skepticism about its financial reporting.
- Related Party Transaction Concealment: The lawsuit also alleges that ADMA failed to disclose related party transactions with Genesis BioPharma Services in SEC filings, despite direct ties to the company's Vice Chairman, which could undermine investor trust in the company's governance practices.
See More
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Kahn Swick & Foti LLC has initiated a class action lawsuit against ADMA Biologics on behalf of investors who suffered losses due to undisclosed material information between August 9, 2024, and March 25, 2026.
- Allegations Details: The lawsuit alleges that ADMA engaged in undisclosed related party transactions, utilized channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about its business and prospects.
- Legal Proceedings: The case is pending in the United States District Court for the District of New Jersey, and investors have until August 10, 2026, to apply for lead plaintiff status to participate in any potential recovery.
- Law Firm Background: Kahn Swick & Foti is recognized as one of the premier securities litigation law firms in the U.S., ranked among the top ten nationally based on total settlement value, focusing on recovering losses for investors affected by corporate fraud or misconduct.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiff by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses and damaging the company's reputation.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder of ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Action Recommendation: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Class Action Filed Against ADMA Biologics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit alleges that ADMA engaged in undisclosed related party transactions, used channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, which severely undermines operational transparency and investor confidence.
- Stock Price Impact: Following the publication of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, indicating market concerns regarding the company's financial health.
- Next Steps: Affected investors are encouraged to contact Bragar Eagel & Squire for more information, demonstrating the firm's commitment to protecting investor rights and providing legal support.
See More
ADMA Biologics Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a class action lawsuit against ADMA Biologics on July 7, 2026, for investors who purchased securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false statements regarding its business operations and financial stability, resulting in artificially inflated stock prices during this period.
- Investor Losses: The lawsuit claims that due to the defendants' misrepresentations, ADMA's securities traded at inflated prices, leading to significant losses for investors when the truth was revealed, highlighting serious issues regarding the company's transparency and compliance.
- Participation Requirements: Investors are encouraged to act promptly and submit forms to join the lawsuit, and those wishing to serve as lead plaintiffs must file by August 10, 2026, indicating the company's commitment to shareholder rights and proactive engagement in legal processes.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has extensive experience in handling class actions, demonstrating its strong capabilities in the legal field and commitment to protecting investor rights.
See More
